Add to balance / Manage account | User: | Log out |
Prospect News home > News index > List of issuers E > Headlines for Endo Pharmaceuticals Holdings Inc. > News item |
Endo at outperform by RBC
RBC Capital Markets analyst Ken Trbovich rated Endo Pharmaceuticals Holdings, Inc. at outperform, above average risk, and reduced third-quarter earnings per share estimates to $0.28 from $0.33. Endo provided something close to quarterly guidance or pre-leased negative results, according to the analyst. RBC cuts its third-quarter 2006 Lidoderm estimate by $10 million and increased its fourth-quarter estimate by $8 million, for an annual Lidoderm estimate at $537.9 million. Shares of the Chadds Ford, Pa.-based pharmaceutical company were down 76 cents, or 2.29%, at $32.37. (Nasdaq: ENDP)
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.